AU2003257110A1 - Polymorphisms for predicting disease and treatment outcome - Google Patents

Polymorphisms for predicting disease and treatment outcome

Info

Publication number
AU2003257110A1
AU2003257110A1 AU2003257110A AU2003257110A AU2003257110A1 AU 2003257110 A1 AU2003257110 A1 AU 2003257110A1 AU 2003257110 A AU2003257110 A AU 2003257110A AU 2003257110 A AU2003257110 A AU 2003257110A AU 2003257110 A1 AU2003257110 A1 AU 2003257110A1
Authority
AU
Australia
Prior art keywords
polymorphisms
treatment outcome
predicting disease
predicting
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003257110A
Other languages
English (en)
Other versions
AU2003257110A8 (en
Inventor
Heinz-Josef Lenz
David Park (Jong-Han)
Jan Stoehlmacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of AU2003257110A1 publication Critical patent/AU2003257110A1/en
Publication of AU2003257110A8 publication Critical patent/AU2003257110A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003257110A 2002-07-31 2003-07-31 Polymorphisms for predicting disease and treatment outcome Abandoned AU2003257110A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40025002P 2002-07-31 2002-07-31
US40024902P 2002-07-31 2002-07-31
US40025302P 2002-07-31 2002-07-31
US40027602P 2002-07-31 2002-07-31
US60/400,250 2002-07-31
US60/400,249 2002-07-31
US60/400,276 2002-07-31
US60/400,253 2002-07-31
PCT/US2003/024065 WO2004011625A2 (en) 2002-07-31 2003-07-31 Polymorphisms for predicting disease and treatment outcome

Publications (2)

Publication Number Publication Date
AU2003257110A1 true AU2003257110A1 (en) 2004-02-16
AU2003257110A8 AU2003257110A8 (en) 2004-02-16

Family

ID=31192379

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003257110A Abandoned AU2003257110A1 (en) 2002-07-31 2003-07-31 Polymorphisms for predicting disease and treatment outcome

Country Status (6)

Country Link
US (4) US7662553B2 (enExample)
EP (4) EP2385137A1 (enExample)
JP (1) JP2005534686A (enExample)
AU (1) AU2003257110A1 (enExample)
CA (1) CA2494262A1 (enExample)
WO (1) WO2004011625A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2390051A1 (en) * 1999-11-15 2001-05-25 University Of Southern California Thymidylate synthase polymorphism for predicting chemotherapeutic response
CA2441350A1 (en) 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
EP2385137A1 (en) 2002-07-31 2011-11-09 University of Southern California Polymorphisms for predicting disease and treatment outcome
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
CN101056990A (zh) * 2004-03-01 2007-10-17 芝加哥大学 表皮生长因子受体基因启动子的多态性
EP1781809A1 (en) * 2004-04-08 2007-05-09 BRAUCH, Hiltrud Ercc2 polymorphisms
EP1774039A4 (en) * 2004-07-01 2009-07-08 Univ Southern California GENETIC MARKERS FOR PREDICTING THE DISEASE AND TREATMENT OUTPUT
GB2424886A (en) 2005-04-04 2006-10-11 Dxs Ltd Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations
WO2007064957A1 (en) * 2005-11-30 2007-06-07 University Of Southern California FCγ POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME
EP1991707A4 (en) 2006-03-03 2012-11-21 Univ Southern California POLYMORPHISMS IN VOLTAGE-CONTROLLED SODIUM CHANNEL ALPHA-1 SUB-UNIT AS A MARKER FOR THERAPY SELECTION
WO2007103814A2 (en) * 2006-03-03 2007-09-13 University Of Southern California Angiogenesis pathway gene polymorphisms for therapy selection
EP1999278A4 (en) * 2006-03-03 2009-12-09 Univ Southern California GENETIC MARKERS FOR PREDICTING THE DISEASE AND TREATMENT OUTPUT
CA2648021A1 (en) 2006-03-31 2007-10-11 Ordway Research Institute, Inc. Prognostic and diagnostic method for cancer therapy
WO2008021483A2 (en) * 2006-08-17 2008-02-21 Ordway Research Institute Prognostic and diagnostic method for disease therapy
FR2906532B1 (fr) * 2006-09-28 2008-12-12 Biomerieux Sa Nouvel oligonucleotide marque
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
CA2675366A1 (en) 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy
CA2675370A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms as sex-specific predictors in cancer therapy
WO2008088860A2 (en) 2007-01-18 2008-07-24 University Of Southern California Polymorphisms in the egfr pathway as markers for cancer treatment
WO2008088855A2 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms as predictors of tumor progression and their use in cancer therapy
US20100184773A1 (en) * 2007-05-18 2010-07-22 Heinz-Josef Lenz Germline Polymorphisms in the Angiogenic Pathway Predict Tumor Recurrence in Cancer Therapy
EP2175722A4 (en) * 2007-07-12 2010-08-25 Tragara Pharmaceuticals Inc PATIENT SELECTION AND THERAPEUTIC PROCEDURES WITH PROSTAGLAND INMETABOLISM MARKERS
BRPI0814542A2 (pt) 2007-07-12 2014-09-30 Tragara Pharmaceuticals Inc Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
DE102007036404A1 (de) * 2007-07-27 2009-01-29 Eberhard-Karls-Universität Tübingen Universitätsklinikum Nachweis der Platinresistenz
CN102014891B (zh) * 2008-03-14 2013-12-18 比奥纽默里克药物公司 增加癌症患者存活时间的化合物的组合物和使用方法
EP2283148A4 (en) * 2008-04-25 2011-11-30 Integrated Bioscience Solutions Llc CYTOLOGICAL METHODS FOR CANCER SCREENING
EP2285976A4 (en) * 2008-05-15 2011-10-26 Univ Southern California ERCC-1 EXPRESSION AS A PROGNOSIS FOR CHEMOTHERAPEUTIC RESULTS
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
CN102405044A (zh) 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
US8568968B2 (en) 2009-04-13 2013-10-29 University Of Southern California EGFR polymorphisms predict gender-related treatment
WO2010124239A2 (en) * 2009-04-24 2010-10-28 University Of Southern California Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
EP2311977A1 (en) * 2009-10-15 2011-04-20 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting responsiveness of a patient to a chemoradiation treatment
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
WO2013090620A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
US11035005B2 (en) 2012-08-16 2021-06-15 Decipher Biosciences, Inc. Cancer diagnostics using biomarkers
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断系统和方法
CN110506127B (zh) 2016-08-24 2024-01-12 维拉科特Sd公司 基因组标签预测前列腺癌患者对术后放射疗法应答性的用途
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
US12497660B2 (en) 2017-08-04 2025-12-16 Veracyte SD, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
RU2732336C1 (ru) * 2020-01-14 2020-09-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ прогнозирования эффективности неоадъювантной химиолучевой терапии при аденокарциноме прямой кишки

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
EP0500727B1 (en) 1989-11-13 1998-01-21 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal dna
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
EP0636186B1 (en) 1992-04-03 1998-11-25 The Perkin-Elmer Corporation Probe composition and method
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
WO1994021822A1 (en) 1993-03-19 1994-09-29 Sequenom, Inc. Dna sequencing by mass spectrometry via exonuclease degradation
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5705336A (en) * 1995-03-07 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Assay for sensitivity of tumors to DNA-platinating chemotherapy
US5571676A (en) 1995-06-07 1996-11-05 Ig Laboratories, Inc. Method for mismatch-directed in vitro DNA sequencing
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US5985561A (en) * 1996-06-03 1999-11-16 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery FC receptor polymorphism
CA2390051A1 (en) * 1999-11-15 2001-05-25 University Of Southern California Thymidylate synthase polymorphism for predicting chemotherapeutic response
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
AU2001255226A1 (en) * 2000-03-31 2001-10-15 University Of Southern California Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibility
US6518416B1 (en) * 2000-12-01 2003-02-11 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US7049059B2 (en) * 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
JPWO2003004640A1 (ja) * 2001-07-05 2004-10-28 大鵬薬品工業株式会社 抗癌剤感受性測定用ｄｎａアレイ
EP1436427B1 (en) * 2001-10-19 2008-08-06 Centre Hospitalier Régional et Universitaire de Tours Methods and compositions to evaluate antibody treatment response
EP2385137A1 (en) 2002-07-31 2011-11-09 University of Southern California Polymorphisms for predicting disease and treatment outcome
CA2503027A1 (en) * 2002-10-21 2004-05-06 University Of Medicine And Dentistry Of New Jersey Thymidylate synthase polymorphisms for use in screening for cancer susceptibility
EP1905847A3 (en) * 2003-01-10 2008-07-02 Pangaea Biotech, S.A. Assay device of XPD/ERCC2 gene polymorphisms for the correct administration of chemotherapy in lung cancer
US9109255B2 (en) * 2004-06-18 2015-08-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining responsiveness to antibody therapy
EP1774039A4 (en) * 2004-07-01 2009-07-08 Univ Southern California GENETIC MARKERS FOR PREDICTING THE DISEASE AND TREATMENT OUTPUT
WO2007064957A1 (en) 2005-11-30 2007-06-07 University Of Southern California FCγ POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME
EP1999278A4 (en) * 2006-03-03 2009-12-09 Univ Southern California GENETIC MARKERS FOR PREDICTING THE DISEASE AND TREATMENT OUTPUT
EP1991707A4 (en) * 2006-03-03 2012-11-21 Univ Southern California POLYMORPHISMS IN VOLTAGE-CONTROLLED SODIUM CHANNEL ALPHA-1 SUB-UNIT AS A MARKER FOR THERAPY SELECTION
WO2007103814A2 (en) * 2006-03-03 2007-09-13 University Of Southern California Angiogenesis pathway gene polymorphisms for therapy selection
WO2008088855A2 (en) 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms as predictors of tumor progression and their use in cancer therapy
EP2109686A2 (en) 2007-01-18 2009-10-21 University Of Southern California Genetic markers for predicting responsiveness to combination therapy
AU2008205471A1 (en) 2007-01-18 2008-07-24 University Of Southern California Tissue factor promoter polymorphisms
CA2675366A1 (en) 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy
WO2008088860A2 (en) 2007-01-18 2008-07-24 University Of Southern California Polymorphisms in the egfr pathway as markers for cancer treatment
EP2126126A2 (en) 2007-01-18 2009-12-02 University Of Southern California Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy
CA2675370A1 (en) 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms as sex-specific predictors in cancer therapy
US9031642B2 (en) 2013-02-21 2015-05-12 Medtronic, Inc. Methods for simultaneous cardiac substrate mapping using spatial correlation maps between neighboring unipolar electrograms

Also Published As

Publication number Publication date
EP1540012A4 (en) 2006-03-22
US20130196955A1 (en) 2013-08-01
WO2004011625A3 (en) 2004-11-11
EP2385137A1 (en) 2011-11-09
EP2385138A1 (en) 2011-11-09
EP2385139A1 (en) 2011-11-09
US20100173922A1 (en) 2010-07-08
WO2004011625A2 (en) 2004-02-05
CA2494262A1 (en) 2004-02-05
AU2003257110A8 (en) 2004-02-16
US20060094012A1 (en) 2006-05-04
EP1540012A2 (en) 2005-06-15
JP2005534686A (ja) 2005-11-17
US20120122946A1 (en) 2012-05-17
US7662553B2 (en) 2010-02-16

Similar Documents

Publication Publication Date Title
AU2003257110A1 (en) Polymorphisms for predicting disease and treatment outcome
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
AU2003294355A1 (en) Ca125 gene and its use for diagnostic and therapeutic interventions
AU2003301347A1 (en) Methods for monitoring treatment of disease
AU2002325435A1 (en) Medication and method for treating pathological syndrome
AU2003284287A1 (en) Physician access system
AU2003266291A1 (en) Single nucleotide polymorphisms predicting adverse drug reactions and drug efficacy in cardiovascular disease
AU2003212850A1 (en) Methods and compositions for treating cardiovascular disease
AU2003293099A1 (en) Treatment of dna damage related disorders
AU2003222449A1 (en) Medicine for treating cancer
AU2003260356A1 (en) An expert system for clinical outcome prediction
EP1576109A3 (en) Methods and compositions for categorizing patients
AU2003223780A1 (en) Treatment for pompe disease
AU2003301348A1 (en) Compositions and methods for diagnosing and treating autoimmune disease
AU2003219857A1 (en) Process for treating disease
AU2002311359A1 (en) Device for controlling and evaluating physiological processes
AU2003205174A1 (en) Molecules for disease detection and treatment
AU2003201159A1 (en) Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
AU2003284166A1 (en) Methods for diagnosing and treating pre-term labor
AU2003220903A1 (en) Method of judging risk of peiodontal disease
AU2003202553A1 (en) Genetic polymorphisms predicting cardiovascular disease and medication efficacy
AU2003248679A1 (en) Treating disease using radium-225
GB0229139D0 (en) Gene polymorphisms
AU2003297912A1 (en) Methods for screening compounds for use in the treatment of disease
AU2003289889A1 (en) Methods for the treatment of alzheimers disease and compositions therefore

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase